Investigational drug · Phase 3
RO7204239
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight, Overweight With One Weight Related Comorbidity.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
4
Any phase or sponsor naming "RO7204239"
First trial start
2022
Jun 2, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RO7204239", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Overweight
- Overweight With One Weight Related Comorbidity
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Spinal Muscular Atrophy (SMA)
Approved drugs for the same conditions: Obesity and weight management · Spinal muscular atrophy · Cardiovascular and metabolic · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "RO7204239" as an intervention, largest first.
- A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related ComorbidityPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06965413 · 285 participants · Start May 5, 2025 · Primary completion Sep 3, 2026
Drug: RO7204239; RO7204239 Matching Placebo and 1 more · For: Obesity; Overweight; Overweight With One Weight Related Comorbidity
Sites: Anniston, Alabama; Spring Valley, California; Clermont, Florida · 35 sites in all
- A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular AtrophyPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05115110 · 97 participants · Start Jun 2, 2022 · Primary completion Nov 2, 2026
Drug: RO7204239; Placebo and 1 more · For: Spinal Muscular Atrophy (SMA)
Sites: Boston, Massachusetts; New York, New York; Randwick, Australia · 29 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05548556 · 51 participants · Start Feb 7, 2023 · Primary completion May 2, 2025
Drug: Placebo; RO7204239 · For: Facioscapulohumeral Muscular Dystrophy (FSHD)
Sites: Orange, California; Aurora, Colorado; Fairway, Kansas · 9 sites in all
- A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or ObesityActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07137585 · 30 participants (planned) · Start Sep 30, 2025 · Primary completion Sep 14, 2026
Drug: Placebo; RO7204239 · For: Type 2 Diabetes Mellitus; Obesity; Overweight
Sites: Homburg, Germany
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.